Premium
Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant anti‐tumour effect
Author(s) -
Martín Alejandro,
GarcíaSanz Ramón,
Hernández José,
Bladé Joan,
Suquía Begoña,
FernándezCalvo Javier,
González Marcos,
Mateo Gema,
Orfao Alberto,
San Miguel Jesus F.
Publication year - 2002
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2002.03549.x
Subject(s) - medicine , oncostatin m , multiple myeloma , bone remodeling , bone resorption , bone disease , interleukin 6 , gastroenterology , cytokine , osteoporosis
Summary. Twelve patients with smouldering or indolent multiple myeloma (MM) received 12 courses of intravenous pamidronate as a single agent to evaluate both the antitumour and bone metabolism effects. One patient achieved minor response, eight had stable disease, and three – all indolent MM – showed disease progression. Serum interleukin 6 (IL‐6), IL‐1β and Oncostatin‐M remained stable throughout the study, while tumour necrosis factor‐α increased. Bone density significantly increased after four and 12 courses compared with baseline. Markers for bone resorption and bone formation decreased with treatment. These results suggest that pamidronate treatment reduces bone turnover in smouldering or indolent MM, but has no significant antitumour effect.